Xiao Xu1, Qing-Hong Ke, Zhe-Xin Shao, Jian Wu, Jun Chen, Lin Zhou, Shu-Sen Zheng. 1. Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, College of Medicine, Key Lab of Combined Muti-Organ Transplantation, Ministry of Health, Zhejiang University, Hangzhou, 310003, China.
Abstract
BACKGROUND: Many patients with hepatocellular carcinoma (HCC) who undergo liver transplantation (LT) subsequently develop tumor recurrence; this is the main factor affecting long-term survival after LT. Factors associated with tumor recurrence should be determined to improve the outcome of LT. The purpose of the study was to evaluate the value of alpha-fetoprotein (AFP) in forecasting tumor recurrence after LT for patients with HCC. METHODS: AFP data before and after LT for 97 patients with HCC who underwent LT in our center were analyzed retrospectively. RESULTS: The mean follow-up time was 17.1 +/- 2.1 months for all 97 patients, overall tumor recurrence rate was 32.9% (32/97), and mean recurrence time was 7.2 +/- 3.2 months. The most common tumor recurrence sites were liver, lung, skeleton, and other sites. Pre-transplant AFP levels >400 ng/ml were associated with higher tumor recurrence. Post-transplant AFP levels not decreasing to <or=20 ng/ml within 2 months were also indicative of higher risk of recurrence. CONCLUSIONS: Pre-transplant AFP and the dynamic change of AFP after LT were valuable in predicting tumor recurrence after LT for patients with HCC.
BACKGROUND: Many patients with hepatocellular carcinoma (HCC) who undergo liver transplantation (LT) subsequently develop tumor recurrence; this is the main factor affecting long-term survival after LT. Factors associated with tumor recurrence should be determined to improve the outcome of LT. The purpose of the study was to evaluate the value of alpha-fetoprotein (AFP) in forecasting tumor recurrence after LT for patients with HCC. METHODS:AFP data before and after LT for 97 patients with HCC who underwent LT in our center were analyzed retrospectively. RESULTS: The mean follow-up time was 17.1 +/- 2.1 months for all 97 patients, overall tumor recurrence rate was 32.9% (32/97), and mean recurrence time was 7.2 +/- 3.2 months. The most common tumor recurrence sites were liver, lung, skeleton, and other sites. Pre-transplant AFP levels >400 ng/ml were associated with higher tumor recurrence. Post-transplant AFP levels not decreasing to <or=20 ng/ml within 2 months were also indicative of higher risk of recurrence. CONCLUSIONS: Pre-transplant AFP and the dynamic change of AFP after LT were valuable in predicting tumor recurrence after LT for patients with HCC.
Authors: E Regalia; J Coppa; A Pulvirenti; R Romito; M Schiavo; L Burgoa; V Mazzaferro Journal: Transplant Proc Date: 2001 Feb-Mar Impact factor: 1.066
Authors: M Merli; G Nicolini; F Gentili; G Novelli; M Iappelli; G Casciaro; U Di Tondo; I Pecorella; A Marasco; A Onetti Muda; F Nudo; G Mennini; S Ginanni Corradini; O Riggio; P Berloco; A F Attili; M Rossi Journal: Transplant Proc Date: 2005 Jul-Aug Impact factor: 1.066
Authors: Timothy M Pawlik; Keith A Delman; Jean-Nicolas Vauthey; David M Nagorney; Irene Oi-Lin Ng; Iwao Ikai; Yoshio Yamaoka; Jacques Belghiti; Gregory Y Lauwers; Ronnie T Poon; Eddie K Abdalla Journal: Liver Transpl Date: 2005-09 Impact factor: 5.799
Authors: J Figueras; L Ibañez; E Ramos; E Jaurrieta; J Ortiz-de-Urbina; F Pardo; J Mir; C Loinaz; L Herrera; P López-Cillero; J Santoyo Journal: Liver Transpl Date: 2001-10 Impact factor: 5.799
Authors: Steven-Huy Han; K Rajender Reddy; Emmet B Keeffe; Consuelo Soldevila-Pico; Robert Gish; Raymond T Chung; Bulent Degertekin; Anna Lok Journal: Clin Transplant Date: 2010-11-16 Impact factor: 2.863